CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 754 enrolled
Drug / intervention
Bedaquiline +7 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02754765
NCT02754765Phase 3Completed
CompareCT.gov

Evaluating Newly Approved Drugs for Multidrug-resistant TB (endTB): A Clinical Trial

Médecins Sans Frontières, France·interventional·Posted Apr 28, 2016·Updated Feb 10, 2025

In Brief

A Phase 3 clinical trial evaluating Bedaquiline, Delamanid, and 6 other interventions for Tuberculosis, Multidrug-Resistant and 2 related conditions. Completed, enrolled 754 participants across 12 sites in 7 countries.

Detailed Summary

endTB Clinical Trial a Phase III, randomized, controlled, open-label, non-inferiority, multi-country trial evaluating the efficacy and safety of five new, all-oral, shortened regimens for multidrug-resistant tuberculosis (MDR-TB).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsTuberculosis, Multidrug-Resistant, Infection, Bacterial, Pulmonary Tuberculoses
CountriesGeorgia, India, Kazakhstan, Lesotho, Pakistan, Peru, South Africa
CollaboratorsPartners in Health, Harvard Medical School (HMS and HSDM), Epicentre, Institute of Tropical Medicine, Belgium, Socios En Salud, Peru, Interactive Research and Development

Timeline

Phase 3CompletedFinished
2017201820192020202120222023202420252026
First PostedApr 28, 2016
Enrollment StartDec 1, 2016
Primary CompletionJun 1, 2023
TodayJul 2, 2026
Enrollment to primary: 6.5 yearsPosted 10.2 years ago

Interventions

Bedaquilinedrug

Delamaniddrug

Clofaziminedrug

Levofloxacindrug

Moxifloxacindrug

Linezoliddrug

Pyrazinamidedrug

Control arm MDR-TB regimen, consistent with WHO guidelinesdrug

Control arm MDR-TB regimen, consistent WHO guidelines